Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson’s Disease

Figure 1

Norfluoxetine prevents degeneration of dopamine neurons in the substantia nigra of MPTP-treated mouse. Animals that received PBS as a control (a, b), norfluoxetine (5 mg/kg) alone (c, d), MPTP (e, f), and MPTP and norfluoxetine (g, h) were sacrificed 7 days after the last MPTP injection. SN tissues were processed for immunostaining with a tyrosine hydroxylase (TH) antibody for dopamine (DA) neurons. (b, d, f, h), higher magnification of (a), (c), (e), and (g), respectively. (i) The numbers of TH⁺ cells in the SNpc. Bars represent the means ± SEM of four to six animals per group. significantly different from control; , significantly different from MPTP. SNpc: substantia nigra pars compacta; SNr: substantia nigra reticulata; VTA: ventral tegmental area; Con: control; NF: norfluoxetine. Scale bars: 300 μm (left panel) and 50 μm (right panel).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)